Clinical Quiz: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

News
Article

Our fourth and final quiz on the ESC/EAS 2019 guidelines on dyslipidemia spotlights lifestyle and nonpharmacological intervention recommendations.

HCPLive clinical quiz logo. | Credit: HCPLive

Credit: HCPLive

Few fields in cardiology have experienced the same level of change in recent years as lipidology. Driven by advances in pathophysiology as well as developments in pharmacological therapies, this change has further the role of guideline recommendations a critical component of educating clinicians.

While statin therapy has maintained its role as a mainstay in management of most lipid disorders as a result of their affordability, efficacy, and established safety profile, the aforementioned advances in pathophysiology, as well as the advent of new therapies, have redefined what is considered to be an optimal approach to the management of dyslipidemia for many patients.

In this clinical quiz, the final in our series of 4 quizzes based on the guideline document, we test your knowledge of lifestyle and nonpharmacological interventions from the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk.

Which dietary change is recommended to specifically lower LDL-C levels?


Quizzes in this series:

Quiz 1: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 2: Risk Assessment and Stratification from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 3: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

Quiz 4: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

Editor’s note: This quiz was generated through the use of AI tools.

References

  1. Menter A, Cordoro KM, Elmets CA, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5. Erratum in: J Am Acad Dermatol. 2020 Mar;82(3):574. doi: 10.1016/j.jaad.2020.01.061. PMID: 31703821.
Recent Videos
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
1 KOL is featured in this series.
1 KOL is featured in this series.
Brendon Neuen, MBBS, PhD | Credit: X.com
4 KOLs are featured in this series
4 KOLs are featured in this series
© 2024 MJH Life Sciences

All rights reserved.